ExOne and Fraunhofer IFAM Deepen Partnership on Metal Binder, Materials Development
1.9.2021 15:30:00 EEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, and the Fraunhofer Institute for Manufacturing Technology and Advanced Materials (“Fraunhofer IFAM”), one of the most important independent research institutions in Europe, today announced they are deepening their partnership on binder and materials development projects following the success of CleanFuse™ metal binder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005493/en/
Parts produced by metal binder jetting before (left) and after (right) sintering. © Fraunhofer IFAM (Photo: Business Wire)
Fraunhofer IFAM’s relationship with ExOne on metal binder jetting development spans more than two decades. They have been working together since about 1998, when ExOne, then part of Extrude Hone, launched the world’s first commercial metal binder jetting system, the RTS-300. In recent years, they have jointly refined and optimized CleanFuse, an ExOne binder based on a development by Fraunhofer IFAM. The result is a clean-burning binder for optimal 3D printing of stainless steels and premium metals.
“When we started developing the first binder version on the Innovent, we soon realized we had a major breakthrough. ExOne was immediately very enthusiastic about our development, because of its exceptional green part strength and clean burnout at low curing temperature. Together with ExOne, we refined the binder, which is now CleanFuse,” says Prof. Frank Petzoldt, Deputy Director of Fraunhofer IFAM since 1999.
Following this success, Fraunhofer IFAM and ExOne have decided to intensify their cooperation and are currently working on a CleanFuse version for processing reactive materials such as aluminum and titanium.
“At ExOne, we truly believe in the power of collaboration – of bringing together a diversity of experts and knowledge – to solve complex problems in the best possible way,” said Rick Lucas, ExOne Chief Technology Officer and VP, New Markets. “Fraunhofer IFAM has been a leading collaboration partner for us – helping to improve our understanding of binders, different types of powders, and how they work together through the entire process chain from printing to final sintering to deliver a quality part.”
Fraunhofer IFAM has a strong foundation in the development and processing of metallic and polymer materials as well as comprehensive knowledge of additive manufacturing technologies – especially for sinter-based processes. The institute’s location in Bremen is fully equipped for sinter-based additive manufacturing and offers all technologies for the printing, depowdering, debinding and sintering of metal parts. The researchers have special know-how around metal powders, binders and their interaction. For research and development in the field of metal binder jetting, they work with a range of ExOne printers starting with the Innovent+ for material and process development. Three printers feature ExOne’s patented Triple Advanced Compaction Technology (ACT) delivering industry- leading green part density. Recently, the institute has put the X1 25Pro® production-speed metal binder jetting system into operation in order to investigate feasibility in context of pilot and pre-series production. Manufacturers interested in metal binder jetting are welcome to schedule a visit to Fraunhofer IFAM Bremen to learn more about the technology and the application possibilities in their fields.
http://www.ifam.fraunhofer.de/de/Presse/Downloads.html
About Fraunhofer IFAM
The Fraunhofer IFAM is one of the most important independent research institutions in Europe for adhesive bonding technology, surfaces, shaping and functional materials. Research and development primarily address industries with special significance for future viability: aviation, automotive, energy technology, medical technology and life sciences, and maritime technologies. At our institute’s five locations – Bremen, Dresden, Stade, Wolfsburg and Braunschweig – as well as at the Test Center for Maritime Technologies on Helgoland – we put our central principles into practice: scientific excellence, a focus on the application of technology, measurable utility at the highest quality for customers. www.ifam.fraunhofer.de
About ExOne
ExOne is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005493/en/
Contact information
Sarah Webster
Chief Marketing Officer, ExOne
724-516-2336
sarah.webster@exone.com
Randy Eisinger M. A.
Head of Corporate Communications, Fraunhofer IFAM
Phone +49 421 2246-252
randy.eisinger@ifam.fraunhofer.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom